-
Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis -
Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis -
Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis -
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis - Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility
-
A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study -
Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies -
A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months -
Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis -
A network medicine approach to discover common novel drug target mechanisms across autoimmune diseases - A molecular signature response classifier stratifies seropositive rheumatoid arthritis patients based on their likelihood of inadequate response to TNF inhibitor therapies
- A high-confidence definition of therapeutic response in rheumatoid arthritiss using a Monte Carlo simulation approach
-
A molecular signature response classifier predicts the likelihood of eular nonresponse to TNF inhibitor therapies in RA: results from a retrospective cohort analysis -
Network medicine framework for identifying drug-repurposing opportunities for COVID-19 -
A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study